In cardiac surgery, the slow shift to perform coronary bypass graft procedures off-pump has turned anastomotic device technology, a long dormant area of product development, into a hot subject at clinical meetings and attracted the attention of large and small device companies. One start-up, Ventrica, was founded to focus on a new bypass procedure, but shifted its emphasis to an important component of that procedure: an automated coronary anastomotic connector. The company's magnetic technology has given it a head-start on this hardest part of the bypass connector puzzle. Some industry experts and surgeons believe that an easy-to-use, reproducible, automated anastomotic device will boost adoption of off-pump bypass surgery, which has lagged far below initial expectations and will also be essential to the future of robotic surgery. Ventrica's challenge is to attract new groups of surgeons to this approach rather than simply preach to already-converted early adopters.
by Stephen Levin
Revolutions in clinical practice patterns and the device breakthroughs that either cause or accompany those changes are, like their political...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Ellipsis said it will use its new funding to expand its AI-powered voice assistant Sage across health systems. Ellipsis is part of the global vocal biomarker market, which is expected to exceed $9bn by the end of 2033, according to a research market report.
After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.
European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.
The $10m seed extension funding round will be used to launch the second-generation wearable headband with the added SmartSleep AI operating system.
The $10m seed extension funding round will be used to launch the second-generation wearable headband with the added SmartSleep AI operating system.
Despite near-term cost pressures, Intuitive Surgical is expanding manufacturing and R&D in North America and Europe to meet demand for Ion, X and Xi systems.
Capital remains available for good healthtech projects, but it is more concentrated and harder to find than of late. Founders and inventors must know how to unlock it. The BioWales 2025 investor panel told them where they could be going wrong.
